Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
renal cell cancer (RCC), VEGF(R) inhibitor vs. everolimus, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.15 [0.88; 1.50]
1.15 [0.88 ; 1.50 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 714 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-581/CLEAR (mtor), 2021 0.65 [0.53; 0.80]
0.65 [0.53 ; 0.80 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 714 NA not evaluable objective responses (ORR)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.48 [1.26; 1.74]
1.48 [1.26 ; 1.74 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 714 NA not evaluable AE (any grade)detailed results KEYNOTE-581/CLEAR (mtor), 2021 5.28 [0.61; 45.46]
5.28 [0.61 ; 45.46 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.53 [1.09; 2.14]
1.53 [1.09 ; 2.14 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.98 [0.94; 4.14]
1.98 [0.94 ; 4.14 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-581/CLEAR (mtor), 2021 2.20 [1.50; 3.23]
2.20 [1.50 ; 3.23 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 4.84 [0.56; 41.67]
4.84 [0.56 ; 41.67 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.92 [0.06; 57.36]
1.92 [0.06 ; 57.36 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 4.43 [1.66; 11.83]
4.43 [1.66 ; 11.83 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 2.34 [1.31; 4.15]
2.34 [1.31 ; 4.15 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Dysgeusia AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 0.48 [0.02; 14.30]
0.48 [0.02 ; 14.30 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Dysphonia AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 3.85 [0.17; 85.62]
3.85 [0.17 ; 85.62 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.78 [0.93; 3.41]
1.78 [0.93 ; 3.41 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Hypertension AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.25 [0.87; 1.81]
1.25 [0.87 ; 1.81 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 3.85 [0.17; 85.62]
3.85 [0.17 ; 85.62 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 4.40 [0.94; 20.50]
4.40 [0.94 ; 20.50 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 0.73 [0.32; 1.69]
0.73 [0.32 ; 1.69 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Proteinuria AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 2.94 [1.41; 6.12]
2.94 [1.41 ; 6.12 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 0.48 [0.04; 5.29]
0.48 [0.04 ; 5.29 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Stomatitis AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 3.14 [1.32; 7.46]
3.14 [1.32 ; 7.46 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (mtor), 2021 1.94 [0.66; 5.74]
1.94 [0.66 ; 5.74 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable Weight decreased AE (grade 3-4)detailed results Out of scale KEYNOTE-581/CLEAR (mtor), 2021 26.79 [3.61; 198.57]
26.79 [3.61 ; 198.57 ] KEYNOTE-581/CLEAR (mtor), 2021 1 0% 695 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 08:57 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 10,93,79,178,152,80
- treatments: 776,1069,693,1068,900,1084,1016,1323,985,604,1014,1447,1476,1477,777,1027,1028,669,1564,670,1015,1023,506,908